MABLife is a private
biotech company founded in 1999, specialising in the development
of antibody-based therapeutics for the treatment of cancer, ophthalmic diseases, autoimmune & inflammatory disorders and nosocomial infections.
The
Company has a focused portfolio of products in development,
including one product currently in phase I/II and four at different stages of preclinical development.
For cancer indications, MABLife 's products target tumours via several different mechanisms and are being developed to treat a wide range of haematological and solid cancers.
The ophthalmic indications are addressed through an anti-angiogenic activity.